MedTrace Logo

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

NCT00906373 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2018-06-04

Study results available
· View outcomes & findings →

Summary

To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.

Conditions

Interventions

BIOLOGICAL

IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)

intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle

BIOLOGICAL

IMC-A12 (cixutumumab) - 20 mg/kg

intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle

DRUG

Sorafenib

400 milligrams (mg) twice per day orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-10-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00906373 on ClinicalTrials.gov